Sorafenib (Sor), a clinical standard therapy for advanced HCC, significantly increases the intensity of ATF6 immunofluorescence labeled in HCC cells, accompanying with the up-regulated expression of ATF6 protein, suggesting ATF6 pathway may be one of the mechanisms of SOR 38. The gene discussed is ATF6; the disease is hepatocellular carcinoma.